Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Medbox CEO Gives Testimony To DPH Regarding Program Implementation In Massachusetts

HOLLYWOOD, Calif., Feb. 15, 2013 /PRNewswire/ -- Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com), announced that their CEO, Dr. Bruce Bedrick, gave testimony earlier in the week to the Department of Public Health in support of sensible regulations and overall implementation of the medical marijuana program in Massachusetts. 

Dr. Bedrick was one of the first few speakers Wednesday in Worcester and gave testimony, in a standing room only crowd, directly to the DPH whom is charged with implementing the rules and procedures governing the Massachusetts medical marijuana program. Dr. Bedrick proposed easy and convenient access for patients to receive their medicine, but also suggested strict regulatory oversight to prevent abuse and diversion. Massachusetts will only be authorizing a total of 35 dispensaries licenses for the entire state and it is believed that the licensing of the facilities will be finalized by the end of this year.

The CEO was then off to Colorado Thursday where he presented the Amendment 64 advisory panel with an overview of the Medbox technology and how it would be used in Colorado to track taxation, limit abuse, and control inventory more effectively. The appearance in Colorado coincides with a news story on Fox News Denver (KDVR) that is set to air Wednesday February 20 th at 9pm central that prominently features the Medbox technology and has interviews with Dr. Bedrick and an operator that utilizes the Medbox equipment in her dispensary to manage day-to-day operations.

"We are thrilled that regulatory agencies around the country are allowing us to speak with them on how to create a safe, compliant, and transparent model for operation," stated Dr. Bedrick. "Medbox prides itself on being an industry leader and an integral part of the solution and never part of the problem."

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,335.28 -19.12 -0.12%
NASDAQ 3,496.43 -2.54 -0.07%
S&P 500 1,666.29 -1.18 -0.07%
US 10 Yr 1.965% +0.016

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs